Connect Biopharma Holdings Ltd

Connect Biopharma’s insider buys, Phase 1 success of rademikibart and early dermatology data signal growing confidence, a solid cash runway, and potential upside for investors.

James Huang’s sizable buy‑order in Connect Biopharma (CBHL) amid volatile pricing signals insider confidence and a fresh $20M equity round, offering hope that upcoming Phase 2 data may lift a struggling yet promising biopharma.